Introduction
Ovarian cancer accounts for 5% of all cancer deaths in Western countries and is the most frequent cause of gynaecological cancer mortality. The incidence varies with age between 1% and 14%, with a peak rate in the eighth decade and, in the majority of cases, the disease has already spread beyond the pelvic cavity at the time of diagnosis. Although in the last decades the introduction of cisplatin-based chemotherapy resulted in an improvement of patient survival, the percentage of recurrent disease is high even in those patients who achieve a complete response to chemotherapy, so that more than 80% of patients with advanced stage of disease die within 5 years (Copeland-Gershenson 1986) . At present, the prognostic characterisation of ovarian cancer patients, based on clinico-pathological parameters such as stage, histology, grade and residual tumour after surgery, seems to be inadequate, since patients with similar clinicopathological characteristics often experience different clinical outcome. Therefore, the identification of biological factors related to tumour aggressiveness could be relevant in order to identify patients with different prognosis and chance to respond to chemotherapy, thus allowing the selection, at the time of initial diagnosis, of high risk patients needing more aggressive therapy or alternative treatment, and a closer follow-up. Among the biological parameters proposed as possible prognostic factors in ovarian cancer, much attention has been focused on endocrine factors and especially on steroid hormones and their receptors. Although several epidemiological and in vitro studies have demonstrated that, similar to breast and endometrial cancer, ovarian cancer cell biology could be influenced by the biochemical pathways promoted by the interaction of oestrogens and progesterone with their specific receptors (ER, PR), conflicting data have been reported about the possible clinical role of ER and PR in this neoplasm.
The aims of this review are (1) to summarise the information about the influence of steroid hormones and their receptors in the biology of ovarian cancer in in vitro models as well as in primary tumours; (2) to investigate the association of steroid hormone receptor expression with the clinico-pathological parameters and the clinical outcome in ovarian cancer patients; and (3) to report the data in the literature about the rationale and the results of endocrine therapy in ovarian cancer.
Steroid hormone receptors and ovarian cancer
The involvement of endocrine factors in ovarian cancer biology is suggested by several observations: as in breast cancer, an increased incidence of nulliparity and a lower mean number of pregnancies were observed among women with ovarian cancer, while the parity or the use of oral contraceptives have been reported to decrease the risk of ovarian cancer development (Joly et al. 1974 , Casagrande et al. 1979 , McGowan et al. 1979 ). These observations also led to the hypothesis, according to the concept of 'incessant ovulation' (Fathalla 1971) , that the formation of inclusion cysts at the ovarian surface following each ovulation could expose the lining epithelium to abnormally high levels of gonadotrophins or oestrogens (Cramer & Welch 1983) . The disregulation of normal patterns of proliferation and differentiation of the ovarian epithelium could represent the first step for genetic alterations to accumulate and to be transferred to daughter cells, thereby proceeding along a multi-step path of molecular oncogenesis.
Many experimental observations confirm the hypothesis of an involvement of steroid hormones in ovarian cancer biology. Jabara in 1962 demonstrated that the administration of diethylstilboestrol and progesterone was followed by the occurrence of ovarian tumours in dogs. Similar results were also reported by Hoover et al. (1977) . In an in vitro system, the ER-positive ovarian cancer cell line, PE04, showed a 50% increase in growth rate when treated with oestradiol compared with the same cells grown in a steroid-free monolayer cell culture. On the other hand, treatment with physiological doses of oestradiol was not associated with any effect on growth rate of the ER-negative ovarian cancer cell line, NIH:OVCAR-3 (Nash et al. 1989) . Moreover, treatment of PE04 with the anti-oestrogen, 4-hydroxy-tamoxifen, abolished the oestrogen-induced cell proliferation. These results were confirmed by Langdon et al. (1990 Langdon et al. ( , 1993 Langdon et al. ( , 1994 who demonstrated that the growth of ER-positive ovarian cancer cell lines is stimulated by oestradiol at concentrations between 10 -12 and 10 -7 M, while the proliferation rate of ovarian cancer cell lines PEA1, PEA2, PE014, PE016, PE023, which are ER-negative, is not influenced by oestradiol exposure. Finally, oestrogen regulated proteins like PR and pS2 (Langdon et al. 1994) and pro-cathepsin D (Galtier-Dereure et al. 1992) were increased in ER-positive ovarian cancer cells after exposure to oestradiol, suggesting that ovarian cancer cells can frequently keep their molecular endocrine pathways unaltered.
However, it has also been demonstrated that the induction of PR cannot always be considered as a marker of cellular sensitivity to oestrogen-induced proliferation (Nash et al. 1989) .
The ability of oestrogens as well as anti-oestrogens to affect ovarian cancer cell proliferation is generally considered to be determined by interaction with specific oestrogen and progesterone receptors. In this context, the demonstration that 50% of ovarian tumours express ER and PR (see below) emphasised the possible biological impact of steroid hormones on ovarian tumour natural history and also provided a biochemical rationale for some clinical responses reported with anti-oestrogens, progestins or luteinizing hormone-releasing hormone therapy (Ward 1972 , Myers et al. 1981 , Schwartz et al. 1982 , Geisler et al. 1983 , Weiner et al. 1987 .
The expression of steroid hormone receptors has been investigated by many authors in benign and in malignant ovarian tumours. The binding characteristics in terms of affinity, specificity, and capacity appeared to be similar in malignant compared with benign and normal ovarian tissues; however, in malignant tumours, the concentration of ER appears to be generally higher compared with benign tumours or normal ovaries, whereas PR levels seem not to be significantly different in ovarian cancer with respect to the normal counterpart or benign tumours (Bergqvist et al. 1981 , Lantta 1984 , Toppila et al. 1986 , Anderl et al. 1988 .
In Table 1 studies related to steroid hormone receptor expression in primary ovarian cancers are listed. ER positivity was found in 53% of the tumours (range 31-91%), whilst PR positivity was found in 47% of the tumours (range 15-97%). The high variability in the percentage of receptor positivity may be related to the different assay methods (biochemistry, flow cytometry, immunohistochemistry), which are not strictly related: for instance Kommoss et al. (1992) reported a low correlation between radio-receptorial assessment of ER and PR versus immunohistochemical determination. The different cut-off levels (which were arbitrarily chosen between 3 and 50 fmol/mg cytosol protein), the heterogeneity of sample series, and in some cases, the limited number of patients examined could be additional sources of variation. Moreover, in studies utilising the biochemical assay, ER and PR were measured at a single point radiolabelled hormone concentration or by means of saturation curves, which can obviously result in variability in ER and PR determination. Finally, Quinn et al. (1988) reported a high variability in terms of ER and PR positivity in the context of the same tumour and in bilateral ovarian cancers.
The expression of steroid hormone receptors in metastatic deposits of ovarian carcinomas has also been investigated (Table 2) . Toppila et al. (1986) have reported an increased ER expression in omental metastases with respect to primary ovarian tumours, while other authors (Holt 1986, our data) did not find any difference. As far as recurrence of disease is concerned, and Vihko et al. (1983) demonstrated that the percentage of ER positivity and the absolute ER levels are higher in primary tumours than in recurrences. Steroid receptors are rarely present in metastases or recurrences of ovarian cancers when the primary lesions are receptor-negative. Studies examining the distribution of ER and PR according to clinico-pathological parameters in ovarian cancer have given conflicting results. Spona et al. (1983) demonstrated a higher incidence (63%) of ER+/PR+ in patients older than 60 years of age than in younger subjects (36%) whereas other authors (Sevelda et al. 1990 , Scambia et al. 1995 reported that PR positivity is more frequently associated with older age. In most studies, no definitive associations between ER, PR expression and stage of disease have been demonstrated , Gronroos et al. 1984 , Iversen et al. 1986 , Anderl et al. 1988 , Bizzi et al. 1988 , Masood et al. 1989 , Rose et al. 1990 , Slotman et al. 1990 . As far as the relationship between steroid receptors and histology is concerned, some authors reported that endometrioid and serous tumours more frequently contain PR or ER (Quinn et al. 1982 , Ford et al. 1983 , Sutton et al. 1986 , Toppila et al. 1986 , Rose et al. 1990 ) while (Toppila et al. 1983 , Gronroos et al. 1984 , Scambia et al. 1995 . Other authors (Sutton et al. 1986 , Kuhnel et al. 1987 , Anderl et al. 1988 , Bizzi et al. 1988 , Masood et al. 1989 , Harding et al. 1990 , Sevelda et al. 1990 , Slotman et al. 1990 , Scambia et al. 1995 did not find any correlation between steroid hormone positivity and histotype. The relationship between steroid receptors and grade of differentiation is not clear; some authors found that well-differentiated tumours more frequently contain ER (Ford et al. 1983 , Iversen et al. 1986 or both ER and PR (Creasman et al. 1981) , but many other studies (Gronroos et al. 1984 , Sutton et al. 1986 , Toppila et al. 1986 , Kuhnel et al. 1987 , Bizzi et al. 1988 , Masood et al. 1989 , Harding et al. 1990 , Rose et al. 1990 , Sevelda et al. 1990 , Slotman et al. 1990 , Scambia et al. 1995 did not confirm these results.
The association between steroid hormone receptor status and response to chemotherapy has been poorly investigated, although Agarwal et al. (1987) reported a higher incidence of ER positivity in cases with poor response to chemotherapy. Some studies also analysed the effects of chemotherapy exposure in primary ovarian tumours: Sutton et al. (1986) reported that ER levels were lower in ovarian carcinomas after chemotherapy while Richman et al. (1985) reported that there was little if any difference in ER levels before and after chemotherapy as also shown by Holt et al. (1986) , Masood et al. (1989) and Rose et al. (1990) . Lower PR levels have been reported in chemotherapy-exposed ovarian tumours (Sutton et al. 1986 ).
ER and PR expression and survival
The role of ER and PR status as possible prognostic parameters in patients with ovarian cancer has been debated for years (see Tables 3 and 4) .
There is some evidence that ER expression does not play a prognostic role in ovarian cancer (Masood et al. 1989 , Harding et al. 1990 , Rose et al. 1990 , Sevelda et al. 1990 , Slotman et al. 1990 , Scambia et al. 1995 . In our latest experience of 177 primary ovarian cancer patients, no significant association between ER and overall and progression-free survival was observed at any of the cutoff levels tested. On the contrary, the association between PR positivity and a better clinical outcome is debatable.
Although some authors have reported that the presence of PR represents a marker of favourable prognosis (Iversen et al. 1986 , Harding et al. 1990 , Sevelda et al. 1990 , Slotman et al. 1990 , Kommoss et al. 1992 , other studies (Anderl et al. 1988 , Masood et al. 1989 , Scambia et al. 1995 , Geisler et al. 1996 failed to confirm these findings.
It is generally accepted that, since PR is an oestrogeninduced protein, PR positivity can be considered as a marker of functional integrity of the ER-promoted biochemical machinery. In this context, the simultaneous positivity for ER and PR should more precisely specify ER dependence in the group of ER-positive cases. A high rate of concordance between ER and PR positivity in ovarian tumours has been reported (Pollow et al. 1983 , Schwartz et al. 1985 , Bizzi et al. 1988 ) except in the study by Slotman et al. (1990) and the percentage of ovarian cancers which show both ER and PR positivity ranged from 16 to 81% (average 33%). Iversen et al. (1986) reported that simultaneous positivity for ER and PR was associated with a better prognosis with respect to ER-/PRcases, as was also demonstrated by Bizzi et al. (1988) .
The heterogeneity in the results reported may be partially explained by the characteristics of the patient population examined and the association of ER and PR with clinical features of good prognosis: in some series low malignant potential tumours or mixed subtypes (Anderl et al. 1988 , Masood et al. 1989 (1995, 1996) 96 na na >0.05 ns Kommoss et al. (1992) 87 11 25 ns na nr, not reached; na, not available; ns; not significant. , Sevelda et al. 1990 ) have been included in the statistical analysis.
Iversen et al. (1986) , for instance, observed that expression of high PR levels was mainly confined to welldifferentiated, early stage ovarian cancer patients. Similarly, in the study by Harding et al. (1990) there was a significant excess of PR+ tumours in the early stage disease category and in those patients who had received the best cyto-reductive surgery and were submitted to cisplatin-based chemotherapy. Moreover, PR positivity was strongly associated with younger age and better response to chemotherapy in the study by Sevelda et al. (1990) .
Finally, some discrepancies could also be related to the choice of different cut-off levels: in their study, Slotman et al. (1990) stratified tumours as negative, low positive and high positive for steroid receptors, considering the value of 30 fmol/mg cytosol protein (much higher than usual) as the best cut-off level for positivity.
Multivariate analysis taking into account all the clinico-pathological factors and steroid hormone receptor status was carried out by Bizzi et al. (1988) and Sevelda et al. (1990) , who demonstrated that the association of ER positivity with a more favourable prognosis is independent of the other factors. On the other hand, Harding et al. (1990) reported that the favourable prognostic role of ER and PR positivity was not retained when matched with the other clinico-pathological prognostic factors. Similar results have also been reported by Kommoss et al. (1992) and Rose et al. (1990) in a series of 123 ovarian cancer patients.
Correlation between steroid hormone receptors and response to hormonal treatment
Many authors demonstrated that the presence of steroid hormone receptors may be predictive of clinical response to hormonal therapy in breast and in endometrial cancer patients (McGuire 1978 , Creasman et al. 1980 .
As far as ovarian cancer is concerned, several studies have reported the anti-proliferative activity of the antioestrogen tamoxifen on primary ovarian tumours (Runge et al. 1986 , Geisinger et al. 1990 , Scambia et al. 1992 . (1977) Medroxyprogesterone 100-400 mg/day 1 9 44 Mangioni et al. (1981) Medroxyprogesterone 500-800 mg/day 5 15 5-8 Geisler (1983) Megestrol acetate 800-->400 mg/day 10 43 4-65 Hamerlynck et al. (1985a) Medroxyprogesterone 500 mg/d-->1000 mg/week 1 2 5 Sikic et al. (1986) Megestrol acetate 800-->400 mg/day 4 8 4-18 Ahlgren et al. (1993) Megestrol acetate 800-->400 mg/day 0 0 -Modified from Ahlgren et al. (1993) .
-->, doses varying within the range defined. (1996) 20 10 13 4.4 Alhgren et al. (1993) 40-->20 5 17 7-72
Bid, twice a day; -->, doses ranging within the ranges defined. From Ahlgren et al. (1993) .
However, in vitro data showed that ER and PR have a relatively poor predictivity of ovarian tumour cell sensitivity to tamoxifen and medroxyprogesterone acetate (Gronroos et al. 1984) . Similarly, Anderl et al. (1988) demonstrated that additional anti-oestrogen therapy had no influence on the clinical outcome of ovarian cancer patients. Moreover, the response to hormonal therapy does not always seem to be associated with the presence or the absolute levels of oestrogen receptor (Runge et al. 1986 , Scambia et al. 1992 , suggesting the possibility that antioestrogens also act via a binding site distinct from the oestrogen receptor (Runge et al. 1986 ). Studies on the use of endocrine therapy in advanced ovarian cancer showed a wide variation in response rates. Results of the most important studies since the 1960s until today that have tested the efficacy of progestin therapy on ovarian carcinoma are shown in Table 5 . The data are not encouraging, since only Geisler et al. (1983) observed a reasonable response, in 43% of treated patients. This trial included several patients not previously submitted to chemotherapy, or treated with chemotherapy only for a short period. Moreover, in the same study (Geisler 1983) , as in the majority of the studies reported before 1980, the response criteria had not been standardised and were, therefore, subjective.
Many authors have proved the efficacy of tamoxifen on patients with ovarian neoplasms refractory to chemotherapy (Table 6 ). The most important trial has been carried out by the Gynecologic Oncology Group (Hatch et al. 1991) on 105 patients at an advanced stage of disease who received tamoxifen (20 mg per os twice daily) for at least one month. The results have been re-analysed recently by Markman et al. (1996) who observed a response percentage of 13% (median duration 4.4 months).
Data examined suggest that, notwithstanding a response percentage of less than 20%, a significant number of patients with ovarian carcinoma refractory to conventional chemotherapy seem to benefit from hormone therapy, and often obtain a stabilisation of disease without important toxic effects. Further studies are necessary to characterise better from a biological point of view a subgroup of patients possibly responding to endocrine therapy, and to verify the possibility of associating endocrine treatment with chemotherapy. In this context, it is worth noting that tamoxifen can inhibit the clonogenic efficiency of cells from primary ovarian cancer and can effectively synergise with cisplatin in the same experimental model (Scambia et al. 1992) . In the clinical setting, the combination of tamoxifen and cisplatin has been used only in one prospective randomised clinical trial (Schwartz et al. 1989) , which failed to demonstrate any benefit in terms of patient survival of combining the two drugs. However, prospective clinical trials are in progress to assess the clinical significance of adding tamoxifen to cisplatin-containing regimes in ovarian cancer.
Conclusions
Whereas there are several experimental and epidemiological studies which show that steroid hormones and their receptors play an important role in the pathogenesis of ovarian tumours, the clinical implications of ER and PR assessment in terms of definition of high versus low risk patients and prediction of response to treatment is still far from being clarified. Our study on a large series of cases failed to find any association between ER and PR status and clinical outcome, even at different cut-off levels. Furthermore, even if some studies reported that ER and PR positivity seems to characterise subgroups of ovarian cancer patients with a more favourable overall survival, the statistical significance is often of border-line value, and multivariate analysis failed to demonstrate any difference in clinical outcome of receptor-positive versus receptor-negative patients.
Similarly, while a significant direct correlation between the presence of steroid hormone receptors and response to hormonal therapy has been found, there is a general agreement that endocrine treatment is only slightly efficacious in the management of advanced ovarian tumours and it should be reserved for palliation only to a subset of patients failing conventional chemotherapy.
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